Author: David Gay

Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. Roche penned a deal worth up to $1.7 billion for an RNA interference program from SanegeneBio. Daiichi Sankyo stopped development of its first non-DXd candidate. And more.Read More

Read More

By Taylor Nicioli, CNN (CNN) — When plant biologist Jing-Yi Lu was earning his bachelor’s degree in Taiwan, he began to take note of the local flora. He paid particular attention to the lipstick vines, which, in Taiwan, have short, tubelike flowers with a yellowish-green hue. However, in other parts of Asia, lipstick vines areRead More

Read More